Basic Science and Pathogenesis

FDA-approved carbonic anhydrase inhibitors (CAIs) have been shown to attenuate Aβ pathology, neurodegeneration, and cerebrovascular dysfunction in models of Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA), suggesting a key role for CAs as a novel and previously unexplored target...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Alzheimer's & dementia 2024-12, Vol.20 Suppl 1, p.e087670
Hauptverfasser:	Elia, Andrea, Parodi-Rullan, Rebecca M, Vazquez-Torres, Rafael, Carey, Ashley M, Fossati, Silvia
Format:	Artikel
Sprache:	eng
Schlagworte:	Alzheimer Disease - metabolism Alzheimer Disease - pathology Amyloid beta-Peptides - metabolism Animals Brain-Derived Neurotrophic Factor - metabolism Cerebral Amyloid Angiopathy - pathology Disease Models, Animal Humans Mice Mice, Transgenic Myocardium - metabolism Myocardium - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!